News

At the Asian Oncology Society 2023 (AOS 2023), an interim report on the Phase I/II trial of GAIA-102 for patients with microsatellite stable (MSS) advanced gastric/pancreatic cancer with malignant ascites was presented.

At the 65th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology, an interim report on the Phase I trial of GAIA-102 for pediatric solid malignant tumors will be presented.

Cellab Healthcare Service (Cellab HS) and GAIA BioMedicine (GAIA) jointly held a press conference to announce that the two firms had executed a business agreement concerning the production of GAIA-102.

GAIA BIOMEDICINE & TREEFROG THERAPEUTICS ANNOUNCE COLLABORATION FOR THE EXPANSION OF ALLOGENEIC NK-LIKE CELLS AGAINST SOLID TUMORS

Kyushu University Hospital had received IND clearance from the PMDA for a Phase Ⅰ investigator-initiated clinical trial of GAIA-102 for pediatric cancer patients with recurrent and refractory neuroblastoma (“NB”) or solid pediatric malignancies with pulmonary metastases

Kyushu University Hospital had received IND clearance from the PMDA for a Phase Ⅰ/Ⅱ investigator-initiated clinical trial of GAIA-102 for patients with Advanced Gastrointestinal Cancer of Microsatellite Stable (“MSS”) with Malignant Ascites

GAIA BioMedicine Inc. has started Phase Ⅰ/Ⅱ clinical trial of its proprietary GAIA-102, NK-cell-like cells, for Non-Small Cell Lung Cancer

AMED Released to Support a Clinical Trial of GAIA-102 to Treat Pediatric Solid Tumors

Innate Killer Summit 2022 at San Diego, March 30- April 1:

GAIA BioMedicine Closes JPY 1.3 Billion (USD 11.9 Million) Series B Investment to Advance the GAIA-102 Platform, The Panted “Off-The-Shelf” NK Cells Like Cell Therapy Platform, For Versatile Solid Tumors